- Open
- 0.17
- High
- 0.19
- Low
- 0.16
- Close
- 0.19
- Change
- -0.00 (-2.86%)
- Volume
- 4,251,211
| 12 Oct 2026 | 11:40:33 | Correction: Form 8 (DD) - Futura Medical |
| 12 Oct 2026 | 11:28:46 | Form 8 (DD) - Futura Medical |
| 12 Oct 2026 | 11:27:55 | Form 8 (DD) - Futura Medical plc |
| 8 Oct 2026 | 07:00:03 | Board Change and Formal Sale Process Update |
| 18 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 5 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 11 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
Futura Medical plc develops and commercializes consumer health products focused on sexual health. The company’s lead product, Eroxon®, is a clinically proven topical gel for the treatment of erectile dysfunction, available over the counter in multiple markets including Europe and the USA. Futura is also developing WSD4000, a portfolio of topical gels aimed at addressing female sexual dysfunction. The company operates a hybrid business model that combines research and development with commercial partnerships to enhance market reach and sustainability. Futura is based in Guildford, United Kingdom, and targets global consumer healthcare markets.
| 12 Oct 2026 | 11:40:33 | Correction: Form 8 (DD) - Futura Medical |
| 12 Oct 2026 | 11:28:46 | Form 8 (DD) - Futura Medical |
| 12 Oct 2026 | 11:27:55 | Form 8 (DD) - Futura Medical plc |
| 8 Oct 2026 | 07:00:03 | Board Change and Formal Sale Process Update |
| 18 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 5 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 11 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
Futura Medical plc develops and commercializes consumer health products focused on sexual health. The company’s lead product, Eroxon®, is a clinically proven topical gel for the treatment of erectile dysfunction, available over the counter in multiple markets including Europe and the USA. Futura is also developing WSD4000, a portfolio of topical gels aimed at addressing female sexual dysfunction. The company operates a hybrid business model that combines research and development with commercial partnerships to enhance market reach and sustainability. Futura is based in Guildford, United Kingdom, and targets global consumer healthcare markets.
| 7 Oct 2026 | 12:23:11 | Form 8.3 - Futura Medical |
| 4 Sept 2026 |
| AIM movers: Premier African Minerals seeks spproval for share issues and Pri0r1ty Intelligence purchase |
| 3 Sept 2026 | Futura Medical to go up for sale after failure to perform |
| 3 Sept 2026 | AIM movers: Hutchmed licence deal with GSK and Futura Medical assessing potential sale |
| 3 Sept 2026 | Futura Medical launches formal sale process alongside £1.6m placing |
| 1 Sept 2026 | Futura Medical advances Eroxon pipeline as it reshapes US commercial strategy |
| 25 Aug 2026 | FTSE 100 Live: FTSE 250 pulls ahead as oil slides below $90 |
| 7 Oct 2026 | 12:23:11 | Form 8.3 - Futura Medical |
| 4 Sept 2026 |
| AIM movers: Premier African Minerals seeks spproval for share issues and Pri0r1ty Intelligence purchase |
| 3 Sept 2026 | Futura Medical to go up for sale after failure to perform |
| 3 Sept 2026 | AIM movers: Hutchmed licence deal with GSK and Futura Medical assessing potential sale |
| 3 Sept 2026 | Futura Medical launches formal sale process alongside £1.6m placing |
| 1 Sept 2026 | Futura Medical advances Eroxon pipeline as it reshapes US commercial strategy |
| 25 Aug 2026 | FTSE 100 Live: FTSE 250 pulls ahead as oil slides below $90 |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £624m | +0.3% | |
| £363m | -0.5% | |
| £82m | +0.2% | |
| £8m | -0.7% | |
| £3m | -0.4% | |
FUMFutura Medical plc | £3m | -0.9% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £624m | +0.3% | |
| £363m | -0.5% | |
| £82m | +0.2% | |
| £8m | -0.7% | |
| £3m | -0.4% | |
FUMFutura Medical plc | £3m | -0.9% |
